MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 27.03.2024
Ampio Pharmaceuticals Anteile 2011-2026 | AMPE
Anteile Jährlich Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 810 K | 754 K | 13.3 M | 173 M | 131 M | 73.4 M | 65.3 M | 53.8 M | 52 M | 50.2 M | 38.3 M | 34 M | 26 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 173 M | 754 K | 54.7 M |
Anteile Vierteljährlich Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 804 K | 15.1 M | 15.1 M | 805 K | 754 K | 15.1 M | 15.1 M | 15.2 M | 13.4 M | 196 M | 195 M | 193 M | 179 M | 166 M | 159 M | 159 M | 142 M | 115 M | 111 M | 111 M | 96.9 M | 86.3 M | 82.9 M | 74.9 M | 68.2 M | 60.6 M | 57.2 M | 57.2 M | 53.8 M | 52 M | 52 M | 52 M | 52 M | 52 M | 52 M | 52 M | 52 M | 51.9 M | 45 M | 42.1 M | 37.1 M | 37.1 M | 37.1 M | 37 M | 36.5 M | 31.3 M | 31.1 M | 31.1 M | 28.7 M | 28.3 M | 31.1 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 196 M | 754 K | 66.2 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
17.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
54.8 M | $ 219.68 | 1.92 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Seres Therapeutics
MCRB
|
128 M | $ 8.28 | - | $ 1.06 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 19.45 | 1.14 % | $ 909 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Mesoblast Limited
MESO
|
649 M | $ 15.44 | 7.82 % | $ 10 B |  Australia |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
11.5 M | $ 0.67 | -5.25 % | $ 7.67 M | Israel |
 |
Mirum Pharmaceuticals
MIRM
|
50.2 M | $ 90.39 | 2.86 % | $ 4.54 B | USA |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.34 | 1.52 % | $ 342 M | Britain |
 |
MediciNova
MNOV
|
49.1 M | $ 1.45 | - | $ 71.1 M | USA |
 |
CytomX Therapeutics
CTMX
|
138 M | $ 4.37 | 2.95 % | $ 603 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
22.3 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.69 | 1.37 % | $ 16.9 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
130 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
165 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Merck & Co.
MRK
|
2.5 B | $ 117.56 | 1.02 % | $ 294 B | USA |
 |
Marker Therapeutics
MRKR
|
15.3 M | $ 1.37 | 8.73 % | $ 21 M | USA |
 |
Moderna
MRNA
|
389 M | $ 53.09 | 3.41 % | $ 20.7 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
192 M | $ 4.47 | 3.71 % | $ 856 M | Canada |
 |
Homology Medicines
FIXX
|
12.3 M | - | 0.77 % | $ 53.4 M | USA |